Long‐term outcome in 42 pediatric liver transplant patients with alpha 1‐antitrypsin deficiency: a single‐center experience

Hughes MG Jr, Khan KM, Gruessner AC, Sharp H, Hill M, Jie T, Kandaswamy R, Humar A, Payne WD, Gruessner RWG. Long-term outcome in 42 pediatric liver transplant patients with alpha 1-antitrypsin deficiency: a single-center experience. Clin Transplant 2011: 25: 731–736. © 2010 John Wiley & Sons A/S. Abstract:  Introduction:  We examined the long-term outcome of transplantation for alpha 1-antitrypsin deficiency (A1ATD). Method:  Data were reviewed on 42 transplants in 35 children with A1ATD over 42 yr and compared with 129 transplants in 116 children with biliary atresia (BA). Results:  Over 50% of patients were followed up for >10 yr. A1ATD were older than BA at transplantation, median age, 6.0 vs. 1.0 yr (p < 0.0001), and transplanted earlier in the course of liver failure (total bilirubin, 2.7 mg/dL [1.4–6.9] vs. 9.7 mg/dL [2.9–15.4], p = 0.005). Patient survival was greater in A1ATD than BA: one-yr post-transplant, 82.7% vs. 67.9%; five yr, 76.5% vs. 60.2%; and 10 yr, 76.5% vs. 55.9% (p = 0.03). Death-censored graft survival was similar: one-yr post-transplant, 68.4% vs. 66.2%; five yr, 68.4% vs. 55.8%; and 10 yr, 68.4% vs. 52.5% (p = 0.2). Deaths were from infection, hemorrhage, and graft failure <6 months post-transplant. Patient survival improved at five yr from 33.3% pre-cyclosporine (CSA) (1969–1984) (n = 6) to 76.5% in the CSA era (1985–1994) (n = 17) and 100% with tacrolimus (1995–2006) (n = 12) (p = 0.007). Conclusions:  The age at transplantation and the degree of liver dysfunction were related to the differences in graft and patient survival between A1AT and BA.